According to the latest report published by Credence Research, Inc. “Short Bowel Syndrome Market — (Drug Type — GLP-2, Glutamine, Growth Hormone and Other Drugs): Market Growth, Future Prospects and Competitive Analysis, 2017–2025,” the short bowel syndrome market was valued at US$ 315.1 million in 2016 and is anticipated to achieve US$ 2.901.0 million by 2025, increasing to CAGR by 27.5 per cent from 2017 to 2025.
Browse the full report at https://www.credenceresearch.com/report/short-bowel-syndrome-market
Market Insights
Short bowel syndrome is a complex disease group that happens owing to a tiny and/or big intestine malfunction. Individuals with short bowel syndrome display bad absorption of nutrients such as water, fats, carbohydrates, vitamins, minerals and other essential components leading to malnutrition, weight loss. In some instances, however, short bowel syndrome can lead to serious, debilitating and life-threatening complications. There is no specific cure for this disease but the surgical removal (resection) of half or more of the small intestine is efficient. Short bowel syndrome can lead to Crohn’s disease, injury or small intestine trauma. Such complications make a important contribution to the development of the market for short bowel syndrome. On the basis of drugs, the market is segmented into GLP-2, glutamine, growth hormone and others. GLP-2 is presently the biggest drug market in the short bowel syndrome industry as it is sold in the U.S. and Europe under the brand names Gattex and Revestive in Europe and other global markets. Drugs presently have orphan drug status, and the exclusivity of drugs in the therapy of short bowel syndrome would further generate enormous revenues during the forecast period.
Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/58584
North America held the largest market in the short bowel syndrome market with U.S. being the highest grossing country. The major factor driving the U.S. short bowel syndrome market is the rising prescription of Gattex, which is the only approve drug in the U.S. Moreover, the increasing demand for growth hormones and glutamine are further driving the short bowel market in the U.S. Europe held the second largest market as in the U.S., approximately 6,000–7,000 SBS patients are dependent on parenteral support with a similar prevalence in Europe. Revestive is the highest grossing drug in the Europe which is marketed by Shire, plc. Moreover, efficient reimbursement scenario in North America and Europe would further drive the market for short bowel syndrome during the forecast period.
Market Competition Assessment:
The short bowel syndrome market comprises large number of pharmaceutical giants operating in the market. Shire holds the largest market share in the short bowel syndrome market. The companies include Merck KGaA, and Emmaus Life Sciences, Inc, Nutrinia Ltd, GlyPharma Therapeutics, OxThera, Ardelyx, Inc, and others.
Key Market Movements:
- Growing prescriptions of Gattex and Revestive in U.S. and Europe respectively is boosting the growth of the short bowel syndrome market.
- Moreover, the increasing demand for growth hormones and glutamine are further driving the short bowel market in the U.S. and Europe.
By Drug Type
GLP-2
Glutamine
Growth Hormone
Others
By Geography Segment
North America
Europe
Asia Pacific (APAC)
Middle East & Africa (MEA)
Latin America
Do Inquiry before buying report at https://www.credenceresearch.com/inquiry-before-buying/58584
Browse the full report at https://www.credenceresearch.com/report/short-bowel-syndrome-market
Market Insights
Short bowel syndrome is a complex disease group that happens owing to a tiny and/or big intestine malfunction. Individuals with short bowel syndrome display bad absorption of nutrients such as water, fats, carbohydrates, vitamins, minerals and other essential components leading to malnutrition, weight loss. In some instances, however, short bowel syndrome can lead to serious, debilitating and life-threatening complications. There is no specific cure for this disease but the surgical removal (resection) of half or more of the small intestine is efficient. Short bowel syndrome can lead to Crohn’s disease, injury or small intestine trauma. Such complications make a important contribution to the development of the market for short bowel syndrome. On the basis of drugs, the market is segmented into GLP-2, glutamine, growth hormone and others. GLP-2 is presently the biggest drug market in the short bowel syndrome industry as it is sold in the U.S. and Europe under the brand names Gattex and Revestive in Europe and other global markets. Drugs presently have orphan drug status, and the exclusivity of drugs in the therapy of short bowel syndrome would further generate enormous revenues during the forecast period.
Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/58584
North America held the largest market in the short bowel syndrome market with U.S. being the highest grossing country. The major factor driving the U.S. short bowel syndrome market is the rising prescription of Gattex, which is the only approve drug in the U.S. Moreover, the increasing demand for growth hormones and glutamine are further driving the short bowel market in the U.S. Europe held the second largest market as in the U.S., approximately 6,000–7,000 SBS patients are dependent on parenteral support with a similar prevalence in Europe. Revestive is the highest grossing drug in the Europe which is marketed by Shire, plc. Moreover, efficient reimbursement scenario in North America and Europe would further drive the market for short bowel syndrome during the forecast period.
Market Competition Assessment:
The short bowel syndrome market comprises large number of pharmaceutical giants operating in the market. Shire holds the largest market share in the short bowel syndrome market. The companies include Merck KGaA, and Emmaus Life Sciences, Inc, Nutrinia Ltd, GlyPharma Therapeutics, OxThera, Ardelyx, Inc, and others.
Key Market Movements:
- Growing prescriptions of Gattex and Revestive in U.S. and Europe respectively is boosting the growth of the short bowel syndrome market.
- Moreover, the increasing demand for growth hormones and glutamine are further driving the short bowel market in the U.S. and Europe.
By Drug Type
GLP-2
Glutamine
Growth Hormone
Others
By Geography Segment
North America
Europe
Asia Pacific (APAC)
Middle East & Africa (MEA)
Latin America
Do Inquiry before buying report at https://www.credenceresearch.com/inquiry-before-buying/58584
No comments:
Post a Comment